Future investigations should focus on the direct modulation of Lp(a)-OxPL pathways in AF through clinical trials, exploring agents such as PCSK9 inhibitors and antisense oligonucleotides to reduce Lp(a) levels. The gene discussed is LPA; the disease is atrial fibrillation.